Circulating biomarkers to monitor cancer progression and treatment

Rapisuwon, Suthee; Vietsch, Eveline E.; Wellstein, Anton

doi:10.1016/j.csbj.2016.05.004

Cited by 128 publications

(109 citation statements)

References 164 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…These assays measure the extracellular or "leaked" levels of otherwise intracellular DNA and RNA, a phenomenon that occurs very frequently in response to tissue destruction. In some organs, even small lesions may cause sufficient cell membrane destruction and consequent DNA, RNA, and protein leakage; these leaked components will then enter systematic circulation [5]. However, the highly sensitive nature of these assays does not necessarily mean that DNA and RNA are more suitable biomarkers than proteins.…”

Section: Introductionmentioning

confidence: 99%

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Hiwasa¹,

Tomiyoshi²,

Nakamura³

et al. 2017

Immunome Res

214

179

View full text Add to dashboard Cite

Background: The discovery and development of novel biomarkers that could facilitate early diagnosis and thus prevent the progression of atherosclerosis-related diabetes mellitus (DM), cerebral infarction (CI), and cardiovascular disease (CVD) has garnered much research interest. Notably, recent reports have described a number of highly sensitive antibody markers. In this study, we aimed to identify additional antibody markers that would facilitate screening. Methods:The amplified luminescent proximity homogeneous assay (AlphaLISA) method, which incorporates glutathione-or streptavidin-donor beads and anti-human-IgG-acceptor beads, was used to evaluate serum antibody levels in serum samples. The protein array method was used for the initial screening, and peptide arrays were used to identify epitope sites. Results:The protein array identified SH3 domain-binding protein 5 (SH3BP5) as a target antigen of serum IgG antibodies in the sera of patients with atherosclerosis. We prepared recombinant glutathione S-transferase (GST)-fused SH3BP5 protein. Peptide arrays revealed that the epitope site recognized by serum antibodies is located within amino acids 161-174 of SH3BP5. AlphaLISA revealed significantly higher serum antibody levels against both the SH3BP5 protein and peptide in patients with DM, acute-phase CI, transient ischemic attack, CVD or chronic kidney disease (CKD), than in healthy donors. Furthermore, areas under the receiver operating characteristic curves of these antibodies were higher in patients with CKD and DM than in other patients. Spearman correlation analysis revealed associations between the serum antibody levels against SH3BP5 peptide and artery stenosis, hypertension, and smoking. Conclusions:The serum anti-SH3BP5 antibody marker appears to be useful for estimating the progress of atherosclerosis and may discriminate atherosclerosis associated with hypertension and/or habitual smoking.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Hiwasa¹,

Tomiyoshi²,

Nakamura³

et al. 2017

Immunome Res

214

179

View full text Add to dashboard Cite

show abstract

“…Cancer cells secrete genomic fragments into the circulatory system and this provides a novel approach for a cancer diagnostic test (51). CTCs may be potential biomarkers to predict effective therapies in patients with castration-resistant cancer (52,53). Increased levels of blood CTCs are associated with poor survival outcome for patients with prostate cancer (52).…”

Section: Non-invasive Genetic Biomarker Testmentioning

confidence: 99%

The context of prostate cancer genomics in personalized medicine

Liu

2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Prostate cancer is one of the most common types of cancer in males. Heterogeneous genomic aberrations may lead to prostate cancer onset, progression and metastasis. This heterogeneity also contributes to the variety in cancer risk and outcomes, different drug responses and progression, observed between individual patients. Classical prognostic factors, including prostate-specific antigen, Gleason Score and clinical tumor staging, are not sufficient to portray the complexity of a clinically relevant cancer diagnosis, risk prognosis, treatment choice and therapy monitoring. There is a requirement for novel genetic biomarkers in order to understand the oncogenic heterogeneity in a patient-personalized clinical setting and to improve the efficacy of risk prognosis and treatment choice. A number of biomarkers and gene panels have been established from patient sample cohort studies. These previous studies have provided distinct information to the investigation of heterogeneous malignancy in prostate cancer, which aids in clinical decision-making. Biomarker-guided therapies may facilitate the effective selection of drugs during early treatment; therefore, are beneficial to the individual patient. A non-invasive approach allows for convenient and repeated sampling to screen for cancer and monitor treatment response without the requirement for invasive tissue biopsies. With the current availability of numerous advanced technologies, reliable detection of the minimal tumor residues present following treatment may become clinical practice and, therefore, inform further in the field of personalized medicine.

show abstract

“…However, an understanding of where human concentrations are in respect to IC 50 or IC 90 concentrations obtained in vitro can be useful to include in dose-justification arguments. Further, the utility of linking plasma PK and plasma-derived biomarkers to activity within tumor or even patient outcomes (eg, objective response rate, progression-free survival, overall survival, or toxicity) is significantly complex and needs further study 25 but has been accomplished for some targeted agents in solid tumors. 26,27 Considerations of the biologic differences between healthy subjects and cancer patients also need to be well thought out before healthy subject PK-PD relationships are extrapolated to cancer patients.…”

Section: Pharmacokinetic-pharmacodynamic Relationshipsmentioning

confidence: 99%

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

Bullock

Lin

Bilic

2017

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Targeted therapies are now considered an integral component in the treatment armamentarium for many malignancies, and the approach to developing these drugs needs to be refined from the previous cytotoxic paradigm of toxicity-guided dose finding and identification of maximum tolerated dose to a paradigm driven by target activity. Moving away from the toxicity-driven dose finding and justification model requires an integrated approach in order to adequately characterize the risk-benefit of a drug. This approach starts with understanding the importance of collecting samples for pharmacokinetic and pharmacodynamic assessments in all phases of clinical development to fully characterize the pharmacokinetics and identify covariates and then correlating exposure to key markers of safety and efficacy in pharmacometric analyses to perform a robust risk-benefit assessment and establish the right dose. In addition, for oral agents, decisions on administering the drug with respect to food can impact dose among other clinical trial outcomes such as tolerability and patient compliance. Understanding the importance of model-based drug development as a decision-making tool to support drug development through incorporation of all relevant data allows for a robust risk-benefit assessment at key decision points. Utilization of clinical pharmacology tools and assessments throughout development will provide the key components of a successful oncology development program.

show abstract

Circulating biomarkers to monitor cancer progression and treatment

Cited by 128 publications

References 164 publications

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis

The context of prostate cancer genomics in personalized medicine

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

Contact Info

Product

Resources

About